The invention relates to the use of S100A4 (UniProtKB P26447) in the treatment and prevention of symptoms of metabolic syndrome, in particular in the treatment of insulin resistance and type 2 diabetes. This use is preferably indicated in pregnant or breastfeeding women, and in patients with severe heart disease, renal insufficiency and/or liver insufficiency.